The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 16, 2021

Filed:

Sep. 12, 2019
Applicant:

Carnegie Mellon University, Pittsburgh, PA (US);

Inventors:

Marcel P. Bruchez, Pittsburgh, PA (US);

Jianjun He, Changsha, CN;

Yi Wang, Jamaica Plain, MA (US);

Assignee:

Carnegie Mellon University, Pittsburgh, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 41/00 (2020.01); A61K 47/64 (2017.01); C07C 211/43 (2006.01); C07C 233/36 (2006.01); C07C 233/40 (2006.01); C09B 11/10 (2006.01); A61N 5/06 (2006.01); C07K 14/00 (2006.01); C07K 14/71 (2006.01); C09B 11/22 (2006.01);
U.S. Cl.
CPC ...
A61K 41/0057 (2013.01); A61K 47/64 (2017.08); A61N 5/062 (2013.01); C07C 211/43 (2013.01); C07C 233/36 (2013.01); C07C 233/40 (2013.01); C07K 14/001 (2013.01); C07K 14/71 (2013.01); C09B 11/10 (2013.01); C09B 11/22 (2013.01); A61N 2005/0659 (2013.01); C07K 2317/622 (2013.01); C07K 2319/035 (2013.01); C07K 2319/30 (2013.01);
Abstract

Provided herein is a two-component photosensitizer, which demonstrated robust and selective killing effects for transfected HEK cells and affibody targeted A431 cancer cells when exposed to near infrared light excitation. Free MG2I is a pure and stable fluorogen; it is easy to synthesize and modify, and has no toxicity to cells. Unlike conventional photosensitizers, the dye and FAP itself has no photosensitizing effect until they are bound. Also unlike other activation methods, the activation step is achieved by adding the fluorogen, not the presence of the targeted molecule, requiring an 'active' activation instead of a 'passive' activation. This method offers the ability to locally switch-on and selective generation of singlet oxygen at the target site and can be used for a wide variety of molecular targets.


Find Patent Forward Citations

Loading…